KEAP1 and metabolic dysfunction-associated steatotic liver disease: In particular, the phenotypic manifestation of MASLD in females has been associated with an alteration of the KEAP1/NRF2 axis in the hepatocytes, with increased levels of KEAP1 inhibitor and reduced NRF2 expression in the nuclear compartment.